Validations Queue
111,300 candidate doc → node links pending adjudication. Each was auto-generated by cosine similarity ≥ 0.55 between document and prediction embeddings (bge-base-en-v1.5, 768-dim). Showing page 39 of 88, 50 rows by similarity. Adjudicating updates doc_node_links.reviewed=true with the chosen polarity, writes per-link rows to audit_log, and removes the row from this queue. Phase 4 inference will use confirmed corroborates/contradicts links as Bayesian evidence.
Pending (total)
111,300
Reviewed
13
Filtered
4,390
page 39 / 88
Showing on page
50
Filters
URL params control source + min-similarity threshold
Bulk auto-confirm by similarity threshold
Confirm or label (corroborates / contradicts) all unreviewed links above a similarity threshold in one transaction. Each affected row writes a per-link audit_log entry. Capped at 1,000 links per call. Use Preview first.
Source0 selected · 0 visible
Bulk action
| Sim | Doc | Source | Pred | Domain | Prior | |
|---|---|---|---|---|---|---|
| 0.59 | FDA ANDA210386: CANAGLIFLOZIN (CANAGLIFLOZIN) — AUROBINDO PHARMA LTD | fda 2026-04-20 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA218417: DEXTROMETHORPHAN POLISTIREX (DEXTROMETHORPHAN POLISTIREX) — AUROBINDO PHARMA LTD | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA203364: MESNA (MESNA) — RISING | fda 2026-04-09 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA211563: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — ALKEM LABS LTD | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA207974: FINGOLIMOD HYDROCHLORIDE (FINGOLIMOD HYDROCHLORIDE) — ALEMBIC | fda 2026-04-24 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA214055: SELEXIPAG (SELEXIPAG) — RK PHARMA | fda 2026-04-16 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA214618: LENALIDOMIDE (LENALIDOMIDE) — CIPLA | fda 2026-04-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA NDA019901: ALTACE (RAMIPRIL) — KING PHARMS LLC | fda 2026-05-07 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA NDA212306: XPOVIO (SELINEXOR) — KARYOPHARM THERAPS | fda 2026-04-30 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA NDA021303: ADDERALL XR 10 (AMPHETAMINE ASPARTATE) — TAKEDA PHARMS USA | fda 2026-04-23 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA BLA761147: ENNUMO (PEGFILGRASTIM-PCCG) — ACCORD BIOPHARMA INC. | fda 2026-05-07 | IND_012 NVIDIA BioNeMo platform + Evo 2 model fundamentally compresses a century of biology into a decade — Evo 2 achieves 90% accuracy in BRCA1 predictions; AI models will seamlessly transition generated biological designs into practical, synthesized clinical... Jensen Huang | Biotech/Longevity | 68% | |
| 0.59 | FDA NDA019414: CARDIOGEN-82 (RUBIDIUM CHLORIDE RB-82) — BRACCO | fda 2026-05-13 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA211026: MACITENTAN (MACITENTAN) — SEASONS BIOTECH | fda 2026-05-19 | COD_TECH_001 A16/N2-class TSMC process availability materially supports 2027 AI accelerator ramps Codex Research Pack | Semis | 50% | |
| 0.59 | FDA ANDA216910: GLYCOPYRROLATE (GLYCOPYRROLATE) — QUAGEN | fda 2026-05-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA208045: LURASIDONE HYDROCHLORIDE (LURASIDONE HYDROCHLORIDE) — AUROBINDO PHARMA LTD | fda 2026-05-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA021891: CHILDREN'S CLARITIN (LORATADINE) — BAYER HEALTHCARE LLC | fda 2026-05-20 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA208283: EPLERENONE (EPLERENONE) — BRECKENRIDGE | fda 2026-05-20 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA207947: UPTRAVI (SELEXIPAG) — ACTELION | fda 2026-05-23 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.59 | FDA ANDA220104: MIRTAZAPINE (MIRTAZAPINE) — MICRO LABS | fda 2026-05-19 | CMQ_035 HBM4 16-layer stack design (required for Vera Rubin) places unprecedented yield and capacity strain on global memory fabrication facilities. Jensen Huang / Morgan Stanley | Semis/Memory | 68% | |
| 0.59 | FDA ANDA211020: BUPROPION HYDROCHLORIDE (BUPROPION HYDROCHLORIDE) — GRAVITI PHARMS | fda 2026-05-29 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA NDA208400: XATMEP (METHOTREXATE SODIUM) — AZURITY | fda 2026-05-27 | SEM_014 Nvidia's Arizona-based TSMC factory successfully fabricated cutting-edge semiconductors on US soil for first time in decades (October 2025). Jensen Huang | Manufacturing | 86% | |
| 0.59 | FDA NDA022334: AFINITOR (EVEROLIMUS) — NOVARTIS | fda 2026-06-01 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA NDA022334: AFINITOR (EVEROLIMUS) — NOVARTIS | fda 2026-06-01 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA217299: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — MSN | fda 2026-06-03 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA ANDA215552: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — YAOPHARMA CO LTD | fda 2026-06-09 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA218900: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — SAPTALIS PHARMS | fda 2026-06-09 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA090659: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — SUN PHARM INDS INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA078316: OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — BARR LABS INC | fda 2026-06-18 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA077723: HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — STRIDES PHARMA | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA210758: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — SPECGX LLC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA209404: TRAMADOL HYDROCHLORIDE (TRAMADOL HYDROCHLORIDE) — MACLEODS PHARMS LTD | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA040893: MEPERIDINE HYDROCHLORIDE (MEPERIDINE HYDROCHLORIDE) — GENUS | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA090895: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — EPIC PHARMA LLC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA218307: OSELTAMIVIR PHOSPHATE (OSELTAMIVIR PHOSPHATE) — ALEMBIC | fda 2026-06-25 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA090707: METHADONE HYDROCHLORIDE (METHADONE HYDROCHLORIDE) — VISTAPHARM LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA203518: MORPHINE SULFATE (MORPHINE SULFATE) — TRIS PHARMA INC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA090485: TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN (ACETAMINOPHEN) — AMNEAL PHARMS | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA206769: ARGATROBAN IN 0.9% SODIUM CHLORIDE (ARGATROBAN) — TEVA PHARMS USA | fda 2026-06-26 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA209935: KISQALI FEMARA CO-PACK (COPACKAGED) (LETROZOLE) — NOVARTIS | fda 2026-07-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA201452: LENALIDOMIDE (LENALIDOMIDE) — ARROW INTL | fda 2026-06-15 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA219271: CYCLOPHOSPHAMIDE (CYCLOPHOSPHAMIDE) — HETERO LABS LIMITED | fda 2026-04-29 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA079162: TOPIRAMATE (TOPIRAMATE) — INVAGEN PHARMS | fda 2026-04-24 | 232_036 AI drug deployment is very hard to launch in US due to human trials; easy in UAE. Ben Horowitz | Biotech/Longevity | 46% | |
| 0.59 | FDA ANDA207110: BOSENTAN (BOSENTAN) — WATSON LABS INC | fda 2026-04-14 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA090505: DOXYCYCLINE HYCLATE (DOXYCYCLINE HYCLATE) — IMPAX LABS INC | fda 2026-04-09 | 245_009 Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption Peter Diamandis | Biotech/Longevity | 45% | |
| 0.59 | FDA ANDA211537: DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE (DAPAGLIFLOZIN) — TORRENT | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA213267: THALIDOMIDE (THALIDOMIDE) — NATCO | fda 2026-04-24 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA NDA220837: EVDI (TRABECTEDIN) — APOTEX | fda 2026-05-01 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA211182: ANDA211182 ((unspecified)) — HETERO LABS LTD V | fda 2026-04-16 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.59 | FDA ANDA090348: ZIPRASIDONE HYDROCHLORIDE (ZIPRASIDONE HYDROCHLORIDE) — CHARTWELL RX | fda 2026-04-24 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA NDA217180: JAKAFI XR (RUXOLITINIB PHOSPHATE) — INCYTE CORPORATION | fda 2026-05-01 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% |